{
    "clinical_study": {
        "@rank": "87613", 
        "brief_summary": {
            "textblock": "RATIONALE: Inserting the gene for interleukin-12 into a person's skin tumor cells may make\n      the body build an immune response to kill tumor cells.\n\n      PURPOSE: Phase I trial to study the effectiveness of interleukin-12 gene therapy in treating\n      patients who have skin metastases."
        }, 
        "brief_title": "Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases", 
        "condition": "Metastatic Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neoplasms", 
                "Neoplasms, Second Primary"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the safety and toxicity of interleukin-12 gene in patients with spontaneous\n           skin metastases.\n\n        -  Determine the antitumor immune response in patients treated with this regimen.\n\n        -  Compare the toxicity of this regimen administered for 1 week vs 2 weeks in these\n           patients.\n\n        -  Compare the local and systemic antitumor response in patients treated with this regimen\n           administered for 1 week vs 2 weeks.\n\n      OUTLINE: Patients are stratified according to number of tumor sites (1 vs 2 vs 3 or more).\n      Patients are assigned to 1 of 2 treatment arms.\n\n        -  Group A: Patients receive interleukin-12 gene intratumorally over 5 minutes on days 1,\n           3, and 5.\n\n        -  Group B: Patients receive IL-12 gene intratumorally over 5 minutes on days 1, 3, 5, 8,\n           10, and 12.\n\n      Patients with stable or responding disease may receive 1 subsequent course beginning on day\n      29.\n\n      Patients are followed at 3, 6, and 12 months.\n\n      PROJECTED ACCRUAL: A total of 12 patients (6 per treatment group) will be accrued for this\n      study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed solid malignancy\n\n               -  Surgically or medically incurable disease\n\n               -  No standard chemotherapy or radiotherapy exists for this disease\n\n          -  Tumor of at least 0.5 cm but no more than 2.5 cm infiltrating into or underlying the\n             skin\n\n               -  Cutaneous metastases, subcutaneous metastases, or tumor-involved lymph nodes\n                  that are easily palpable\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-1\n\n        Life expectancy:\n\n          -  More than 3 months\n\n        Hematopoietic:\n\n          -  WBC greater than 3,000/mm^3\n\n          -  Platelet count greater than 80,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin less than 2.0 mg/dL\n\n        Renal:\n\n          -  Creatinine less than 2.0 mg/dL\n\n        Other:\n\n          -  HIV negative\n\n          -  No active infections requiring antibiotic, antiviral, or antifungal treatment\n\n          -  No other active malignancy\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  At least 1 month since prior immunotherapy\n\n          -  No concurrent colony-stimulating factors\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 1 month since prior chemotherapy\n\n        Endocrine therapy:\n\n          -  At least 1 month since prior steroids (other than intermittent use as an antiemetic\n             or topical agent)\n\n          -  No concurrent steroids\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  Prior radiotherapy to vaccine site allowed provided there is documentation of\n             progressive disease\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  No prior organ allografts\n\n        Other:\n\n          -  No other concurrent antineoplastic therapy\n\n          -  No other concurrent investigational drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "January 4, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00028652", 
            "org_study_id": "CDR0000069115", 
            "secondary_id": [
                "P30CA014520", 
                "WCCC-CO-9771", 
                "WCCC-HSC-1998-257", 
                "NCI-T98-0025"
            ]
        }, 
        "intervention": {
            "intervention_name": "interleukin-12 gene", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Interleukin-12"
        }, 
        "keyword": "skin metastases", 
        "lastchanged_date": "April 19, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/WCCC-CO-9771"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53792-6164"
                }, 
                "name": "University of Wisconsin Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Treament of Spontaneous Tumor Metastases With IL-12 DNA (NSC #709933): A Phase IB Trial", 
        "overall_official": {
            "affiliation": "University of Wisconsin, Madison", 
            "last_name": "David M. Mahvi, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00028652"
        }, 
        "source": "University of Wisconsin, Madison", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Wisconsin, Madison", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2002", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }, 
    "geocoordinates": {
        "University of Wisconsin Comprehensive Cancer Center": "43.073 -89.401"
    }
}